Effect of oral L-citrulline on brachial and aortic blood pressure defined by resting status: evidence from randomized controlled trials

Table 1 Baseline characteristics of the studies included in the meta-analysis

Author/Year	Countries	Design	Size (M/F)	Age (year±SD)	Status	Dose (g/day)	Duration (wks)	Baseline BP (mm Hg)
Author/Year	Countries	Design	Size (M/F)	Age (year±SD)	Status	Dose (g/day)	Duration (wks)	L- Cit	Placebo
Gonzales 2017	USA	X, DB	12/13	70 ± 5	Healthy/ Hypertension	6	2	M: 130 ± 13/65 ± 8 F: 137 ± 16/77 ± 9
Figueroa 2016	USA	X, DB	16/0	24 ± 8	Healthy	6	2	123 ± 12/68 ± 8	122 ± 8/67 ± 4
Wong 2016	USA	P	0/23	58 ± 4.8	Healthy/ Hypertension	6	8	138 ± 4/81 ± 4	137 ± 4/80 ± 3
Wong 2015	USA	P	0/27	58 ± 3	Healthy/ Hypertension	6	8	140 ± 9/78 ± 7	141 ± 2/80 ± 8
Sanchez-Gonzalez 2013	USA	X	16/0	23 ± 12	Healthy	7–11	2	116 ± 2/59 ± 3
Balderas-Munoz 2012	Mexico	P, DB	24/11	67 ± 9	Systolic heart failure	3	16	113 ± 17/70 ± 12	118 ± 16/77 ± 11
Ochiai 2012	Japan	P, DB	15/0	58.3 ± 4.4	Healthy	5.6	1	136 ± 13/82 ± 7	131 ± 9/85 ± 7
Figueroa 2010	USA	X, DB	17/0	22 ± 4.1	Healthy	6	4	120 ± 12/67 ± 8	121 ± 12/68 ± 8

BP blood pressure; DB double blinding; F female; L- Cit L-citrulline; M male; P parallel controlled trial; SD standard deviation; X cross-over study design

ISSN: 1743-7075